Hydromorphone tablets are intended to relieve moderate to severe acute pain in patients when opioid use is necessary and appropriate.
The tablets are a generic version of Stamford, Conn.-based Purdue Pharma’s Dilaudid tablets.
The India-based drug company’s new tablets represent the 12th approved treatment developed by its Dayton, N.J.-based subsidiary Aurolife.
More articles on the drug market:
Drug shortages force workarounds in Conn. hospitals
4 reasons adults need vaccines just as much as kids
Drugmakers have firm grasp on drug pricing power
